Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder

• Inhibrx Inc (NASDAQ: INBX) announced topline results from a Phase 1 clinical trial of INBRX-101, an optimized recombinant human AAT-Fc fusion protein, in patients with alpha-1 antitrypsin deficiency (AATD).

• AATD is an inherited condition that raises lung and liver disease risks. AAT is a protein that protects the lungs, and the liver makes it.

• Treatment was well tolerated, with no severe or serious adverse events related to the study drug.

• Related: Inhibrx Shares Interim Data On INBRX-106 - Keytruda Combo Therapy In Solid Tumors.

• Drug-related adverse events were predominantly mild, and those few that were moderate in severity were all transient and reversible, with minimal or no symptomatic care.

• No safety-related or PK/PD-related signs of neutralizing anti-drug antibodies were observed.

• Data from the multiple ascending dose cohorts of INBRX-101 at 40, 80, and 120 mg/kg IV every three weeks showed the expected accumulation of functional AAT levels.

• The current standard of care, plasma-derived AAT, dosed once weekly at 60 mg/kg, achieves a Cavg of functional AAT of 17.8 µM over the weekly dosing interval.

• INBRX-101 achieved a mean Cavg of functional AAT of 40.4 µM over the 21-day dosing interval following the third 80 mg/kg dose.

• Price Action: INBX shares are down 10.50% at $15.16 during the market session on the last check Monday.

See more from Benzinga

• Magenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia Trial

• AbbVie, Cugene Ink Licensing Pact For Autoimmune & Inflammatory Disease Candidate

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.